{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.8","upperLimit":"11","value":"3.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"PFS will be estimated using the method of Kaplan-Meier. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), Disease progression in evaluable patients will be defined as one or more of the following:\n\nAny new disease and/or clear progression of evaluable disease; OR 2 fold elevation in CA-125 from its lowest level (either initial level or nadir, whichever is lowest, since study enrollment) combined with CA-125 elevation confirmed by re-assay at any time.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive everolimus PO QD and letrozole PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Everolimus and Letrozole)"}],"paramType":"MEDIAN","populationDescription":"All evaluable patients","reportingStatus":"POSTED","timeFrame":"Time from registration to the first of either disease progression or death from any cause, assessed up to 2 years","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}